medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2011, Number 3

<< Back Next >>

Salud Mental 2011; 34 (3)

Definición e impacto de las depresiones resistentes/refractarias al tratamiento

Tamayo JM, Rosales-Barrera JI, Villaseñor-Bayardo SJ, Rojas-Malpica C

Language: Spanish
References: 48
Page: 247-255
PDF size: 119.41 Kb.


ABSTRACT

Major depressive disorder (MDD) is characterized by high rates of medical morbidity, low productivity, low life expectancy, and high rates of suicide. Therefore, the treatment of depressed patients involves, among others, an early diagnosis and treatment of the disease. Although an increasing number of antidepressants to treat MDD are available, approximately half of the patients do not respond, and near of two-thirds do not achieve remission after a first treatment attempt.
For this project, it was conducted a detailed review using several databases such as MEDLINE, PsycINFO, EMBASE, the Cochrane Library, and LILACS from 1949 to March 2011 crossing terms related to the diagnosis and impact of the DRT. Unfortunately, original publications on DRT in Latin America are scarce and the findings and conclusions of this review have been based almost entirely on Anglo-Saxon scientific evidence.
In a similar manner as described by medical microbiology, a major depressive episode (MDE) can be considered refractory when it has not responded to an adequate treatment with an established therapy. What constitutes an inadequate treatment has been the subject of considerable debate, but most experts would probably say it is the failure to achieve remission. The rationale for this approach is that not achieving remission often results in changes in work performance, increased risk of recurrences, chronicity, suicide, and impaired social functioning.
Before considering a patient as TRD, is necessary to confirm the diagnosis of unipolar MDD ruling out other psychiatric disorders such as bipolar disorder, or other non-psychiatric medical diseases. After clarifying the diagnosis, and in the absence of remission, the physician is confronted with a great diversity of definitions and clinical criteria suggested for DRT. This variety of diagnostic alternatives, rather than enrich the portfolio of treatment options for DRT, often leads to serious discrepancies that hinder the effective management of the DRT.
Unfortunately, more than 50 years after the discovery of the first antidepressants and increased knowledge about the neurobiological mechanisms of MDD and their interactions with the environment, for now there are no uniform guidelines on the definition and treatment of patients with DRT. Perhaps, the most accepted definition of DRT in the literature is that in which an inadequate response after one or two courses of antidepressant treatment with dose optimization, appropriate time of administration (usually between 8 and 12 weeks) and high level of adherence and compliance can be assured.
Among the models proposed for the diagnosis of the DRT, Thase and Rush developed a frequently used tool, although with a predictive value, regarding the outcome of treatment, not systematically evaluated. It is based on five steps or levels that arbitrarily assume that the lack of remission after one single trial with an appropriate treatment is just enough to make a diagnosis of DRT. In addition, certain interventions such as tricyclic antidepressants or monoamine oxidase inhibitors are considered superior to first-line strategies available today.
This review also defines the differential diagnosis of DRT such as pseudo-resistance, chronic depression, bipolar depression and tachyphylaxis, and describes the costs and consequences of DRT with an inadequate intervention.


REFERENCES

  1. Panzarino P Jr. The costs of depression: direct and indirect; treatment versus nontreatment. J Clin Psychiatry 1998;59(supl 20):11-14.

  2. Ustün TB, Ayuso-Mateos JL, Chatterji S et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-392.

  3. Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.

  4. Crown WH, Finkelstein S, Berndt ER et al. The impact of treatmentresistant depression on health care utilization and costs. J Clin Psychiatry 2002;63:963-971.

  5. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-659.

  6. Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry 2005;66(supl 8):5-12.

  7. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006;75:139-153.

  8. Rush AJ, Trivedi JH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917.

  9. Judd LL, Paulus MJ, Schettler PJ et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157:1501-1504.

  10. Miller IW, Keitner GI, Schatzberg AF et al. The treatment of chronic depression, pt 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-619.

  11. Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord 1997;45:5-18.

  12. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62(Supl 16):10-17.

  13. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry 2003;53:640-648.

  14. Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol 2007;17:696-707.

  15. BIREME/PAHO/WHO. Base de datos de Literatura Latinoamericana y del Caribe en Ciencias de la Salud – LILACS: http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&base=LILACS&lang=i&form=F (última búsqueda, marzo 2011).

  16. Souery D, Lipp O, Massat I et al. The characterization and definition of treatment-resistant mood disorders. En: Amsterdam JD, Hornig M, Nierenberg AA (eds.). Treatment-resistant mood disorders. New York: Cambridge University Press; 2001; pp. 3-29.

  17. Rush AJ, Thase ME, Dube S. Research issues in the study of difficult-totreat depression. Biol Psychiatry 2003;53:743-753.

  18. Thase ME, Rush AJ. When at first you don’t succeed: Sequential strategies for antidepressant non-responders. J Clin Psychiatry 1997;58(Supl 13):23-29.

  19. Souery D, Amsterdam J, de Montigny C et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9:83-91.

  20. Berlim MT, Turecki G. Definition, assessment, and ataging of treatment– resistant refractory major depression: A review of current concepts and methods. Can J Psychiatry 2007;52:46-54.

  21. Petersen T, Papakostas GI, Posternak MA et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005;25:336-341.

  22. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: Definition and treatment approaches. J Clin Psychiatry 1990;51(Supl):39-47.

  23. Sharma V, Khan M, Smith A. A closer look at treatment resistant depression: is it due to a bipolar diathesis? J Affect Disord 2005;84:251-257.

  24. Ghaemi SN, Rosenquist KJ, Ko JY et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Pychiatry 2004;161:163-165.

  25. Rybakowski JK, Suwalska A, Lojko D et al. Types of depression more frequent in bipolar than in unipolar affective illness: results of the Polish DEP-BI study. Psychopathology 2007;40:153-158.

  26. Parker GB, Malhi GS, Crawford JG et al. Identifying ‘paradigm failures’ contributing to treatment-resistant depression. J Affect Disord 2005;87:185-191.

  27. Dudek D, Rybakowski JK, Siwek M. Risk factors of treatment resistance in major depression: Association with bipolarity. J Affect Disord 2010;126:268-271.

  28. Nierenberg AA, Alpert JE. Depressive breakthrough. Psychiatr Clin North Am 2000;23:731-742.

  29. Fava M, Kaji J. Continuation and maintenance treatments of major depressive disorder. Psychiatr Ann 1994;24:281-290.

  30. Ghaemi SN, Ko JY, Goodwin FK. ‘‘Cade’s Disease’’ and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002;47:125-134.

  31. Fekadu A, Wooderson SC, Markopoulo K et al. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord 2009;116:4–11.

  32. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.

  33. Burrows GD, Norman TR. Treatment-resistant unipolar depression. En: Lader M, Naber D (eds.). Difficult clinical problems in psychiatry. London: Martin Dunitz; 1999; pp. 57-73.

  34. Dunner DL, Rush AJ, Russell JM et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment resistant depression. J Clin Psychiatry 2006;67:688-695.

  35. Paykel ES, Ramana R, Cooper Z et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-1180.

  36. Kennedy N, Paykel ES. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord 2004;80:135-144.

  37. Joyce PR, Mulder RT, Luty SE et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry 2002;36:384-391.

  38. Mynors-Wallis L, Gath D. Predictors of treatment outcome for major depression in primary care. Psychol Med 1997;27:731-736.

  39. Worthington J, Fava M, Agustin C et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics 1996;37:518-522.

  40. Fava M, Uebelacker LA, Alpert JE et al. Major depressive subtypes and treatment response. Biol Psychiatry 1997;42:568-576.

  41. Rush AJ, Trivedi MH. Treating depression to remission. Psychiatr Ann 1995;25:704-705,709.

  42. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62(Supl 16):26-31.

  43. Malhi GS, Parker GB, Crawford J et al. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand 2005;112:302-309.

  44. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry 2006;67 (Supl 6):16-22.

  45. Ustün TB, Kessler RC. Global burden of depressive disorders: the issue of duration. Br J Psychiatry 2002;181:181-183.

  46. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001;62(Supl.16):18-25.

  47. Nelsen MR, Dunner DL. Clinical and differential diagnostic aspects of treatment-resistant depression. J Psychiatr Res 1995;29:43-50.

  48. Russell JM, Hawkins K, Ozminkowski RJ et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65:341–347.




2020     |     www.medigraphic.com